Advanced

Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.

Kristensen, Lars Erik LU ; Englund, Martin LU ; Neovius, Martin; Askling, Johan; Jacobsson, Lennart LU and Petersson, Ingemar LU (2013) In Annals of the Rheumatic Diseases 72(10). p.1675-1679
Abstract
OBJECTIVE: To study long-term work disability before and after tumour necrosis factor (TNF)-antagonist therapy in patients with psoriatic arthritis (PsA). METHODS: Using the population-based South Swedish Arthritis Treatment Group Register, we identified 191 patients with PsA (median age 43 years, range 18-58 years, 54% men), who between January 2003 and December 2007 started treatment with adalimumab, etanercept or infliximab. We linked data to the Swedish Social Insurance Agency and calculated the proportion of work disability in 30-day intervals from 12 months before the start of treatment until 3 years after. For each patient with PsA we randomly selected four matched reference subjects from the general population. RESULTS: At... (More)
OBJECTIVE: To study long-term work disability before and after tumour necrosis factor (TNF)-antagonist therapy in patients with psoriatic arthritis (PsA). METHODS: Using the population-based South Swedish Arthritis Treatment Group Register, we identified 191 patients with PsA (median age 43 years, range 18-58 years, 54% men), who between January 2003 and December 2007 started treatment with adalimumab, etanercept or infliximab. We linked data to the Swedish Social Insurance Agency and calculated the proportion of work disability in 30-day intervals from 12 months before the start of treatment until 3 years after. For each patient with PsA we randomly selected four matched reference subjects from the general population. RESULTS: At treatment initiation 67% of the patients with PsA were work disabled-that is, either on sick leave (41.5%) or receiving a disability pension (25.3%). Patients sustaining treatment were, on average, work disabled 12.5 days a month at treatment initiation declining to 10.6 days a month after 3 years of treatment. Patients for whom the first treatment course failed were work disabled 16.5 days at treatment start decreasing to 15.6 days after 3 years. The background population were 2.5 days and 3.0 days off work each month, respectively. Regression modelling identified prior work disability status, anti-TNF treatment failure, higher age, female gender and longer disease duration as significant predictors of working disability. CONCLUSIONS: There was a decline in net work disability after initiation of anti-TNF treatment in patients with PsA. Patients withdrawing from treatment had a 50% increased risk of being work disabled. Prior work disability, higher age, female gender and longer disease duration were also associated with long-term work disability. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of the Rheumatic Diseases
volume
72
issue
10
pages
1675 - 1679
publisher
British Medical Association
external identifiers
  • wos:000323906000016
  • pmid:23148309
  • scopus:84883753184
ISSN
1468-2060
DOI
10.1136/annrheumdis-2012-202229
language
English
LU publication?
yes
id
7951970e-9458-4b65-aa73-00cb620c72a0 (old id 3218996)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23148309?dopt=Abstract
date added to LUP
2012-12-03 15:11:23
date last changed
2019-09-11 01:26:59
@article{7951970e-9458-4b65-aa73-00cb620c72a0,
  abstract     = {OBJECTIVE: To study long-term work disability before and after tumour necrosis factor (TNF)-antagonist therapy in patients with psoriatic arthritis (PsA). METHODS: Using the population-based South Swedish Arthritis Treatment Group Register, we identified 191 patients with PsA (median age 43 years, range 18-58 years, 54% men), who between January 2003 and December 2007 started treatment with adalimumab, etanercept or infliximab. We linked data to the Swedish Social Insurance Agency and calculated the proportion of work disability in 30-day intervals from 12 months before the start of treatment until 3 years after. For each patient with PsA we randomly selected four matched reference subjects from the general population. RESULTS: At treatment initiation 67% of the patients with PsA were work disabled-that is, either on sick leave (41.5%) or receiving a disability pension (25.3%). Patients sustaining treatment were, on average, work disabled 12.5 days a month at treatment initiation declining to 10.6 days a month after 3 years of treatment. Patients for whom the first treatment course failed were work disabled 16.5 days at treatment start decreasing to 15.6 days after 3 years. The background population were 2.5 days and 3.0 days off work each month, respectively. Regression modelling identified prior work disability status, anti-TNF treatment failure, higher age, female gender and longer disease duration as significant predictors of working disability. CONCLUSIONS: There was a decline in net work disability after initiation of anti-TNF treatment in patients with PsA. Patients withdrawing from treatment had a 50% increased risk of being work disabled. Prior work disability, higher age, female gender and longer disease duration were also associated with long-term work disability.},
  author       = {Kristensen, Lars Erik and Englund, Martin and Neovius, Martin and Askling, Johan and Jacobsson, Lennart and Petersson, Ingemar},
  issn         = {1468-2060},
  language     = {eng},
  number       = {10},
  pages        = {1675--1679},
  publisher    = {British Medical Association},
  series       = {Annals of the Rheumatic Diseases},
  title        = {Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2012-202229},
  volume       = {72},
  year         = {2013},
}